- Secured Service Contracts for Huons Pipeline Leveraging Platform Technology - PanGen Biotech, a subsidiary of the Huons Group, is expanding its cell-based bioassay service business after securing new bioassay service contracts. PanGen Biotech announced on the 1st that it has recently been awarded contracts from Huons to conduct bioassays for Lirag..

Huons Group Approves All Agenda Items at Annual General Meeting of Shareholders, Commits to Enhancing Shareholder Value - Approved financial statements and key agenda items, including the appointment of directors for Huons Global, Huons, Humedix, HuM&C, and PanGen Biotech - ▲On March 31st, Huons Global CEO Song Soo-young speaks at the 39th Annual Genera..

- Dividend policy for 2026: 200 won per quarter, 800 won total per year - - HuM&C’s first-time year-end dividend set at 200 won per share; record date is April 3 - Huons Group is committed to boosting corporate value through proactive shareholder-friendly dividend policies and various strategic initiatives. Huons Group (Chairman Yoon Sung-tae) a..

Huons Signs Distribution and Co-promotion Agreement with Sanofi Korea for 5 Vaccines, Entering Vaccine Business - Established a new vaccine business unit, leveraging strong injectables sales network with an advanced cold chain system - Huons has signed a distribution and co-promotion agreement for five vaccines with Sanofi on March 25 at Huons Group Headquarters. (From the left) Huons CEO So..

- Exhibited latest solutions in aesthetics, ESWL, and infection control - Huons Meditech participated in ‘KIMES 2026’ from March 19 to 22. The photo shows the exhibition booth. Huons Meditech, a medical device specialist under Huons Group showcased its flagship products, including the extracorporeal shockwave lithotripter, at one of Korea’s leading medi..

- Showcased HyDIFFUZE™ based formulation conversion technology and stand-alone drug product, HYDIZYME™ -   Huonslab’s booth at the Korean Pavilion at ‘BIO CHINA 2026’   Huonslab, a subsidiary of Huons Global introduced its formulation conversion technology using recombinant human hyaluronidase and innovative pipelines at the global bio ind..